soft tissue sarcoma
Conditions
Interventions
Single-arm:Preoperative RT with concurrent Anlotinib
Sponsors
Cancer Hospital of Chinese Academy of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Patients with primary or recurrent soft tissue sarcomas of limbs or trunk (excluding those who need extended resection after unscheduled tumor resection in other hospitals) need to receive radiotherapy after multidisciplinary ward round discussion; 2. Patients aged 18-75 years; 3. Patients with ECoG 0-3 points; 4. Patients with soft tissue sarcomas confirmed by pathology; 5. Patients with assessable lesions; 6. Patients who can tolerate radiotherapy and enrotinib; 7. The female patients or the male patients whose sexual partners are women of childbearing age should take effective contraceptive measures during the whole treatment period and 6 months after the last medication; 8. Patients who can sign informed consent and have follow-up conditions.
Exclusion criteria
Exclusion criteria: 1. Patients who have no gross tumor after unplanned tumor resection; 2. Patients with other complications can not use arotinib: arotinib allergy, active bleeding, ulcer, intestinal perforation, intestinal obstruction, uncontrollable hypertension, grade III- IV cardiac insufficiency (NYHA standard), severe hepatorenal insufficiency (grade IV), etc; 3. Fibrosarcoma of skin protuberant type, patients with sclerofibromatosis; 4. Patients with benign tumors; 5.5-year-old patients with new cancer (except cervical carcinoma in situ or early skin basal cell carcinoma); 6. Patients with soft tissue sarcomas that can be cured by simple dilatation; 7. Patients with previous radiotherapy history of the same site; 8. Patients with distant metastasis (M1); 9. Patients with other serious medical complications who are unable to operate or participate in the study; 10. Patients who have received or intend to receive neoadjuvant chemotherapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Major Wound Complications; | — |
Secondary
| Measure | Time frame |
|---|---|
| Acute toxicities;Late toxicities;extremity function;Quality of Life;2-year local control;2-year overall survival; | — |
Countries
China
Contacts
Public ContactNingning Lu, Shengji Yu, Shulian Wang
Department of Radiotherapy, Cancer Hospital, Chinese Academy of Medical Sciences
Outcome results
None listed